An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients with Relapsed and/or Relapsed-Refractory Multiple Myeloma

Trial Profile

An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients with Relapsed and/or Relapsed-Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Melphalan flufenamide (Primary) ; Dexamethasone; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Oncopeptides
  • Most Recent Events

    • 12 Dec 2017 Results (data cut off: 19 Jlu, 2017; n=45) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 17 Aug 2017 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
    • 17 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top